Although the final conclusions of the study indicated that trametinib does not demonstrate significant clinical activity in patients with non-V600 BRAF mutations, a patient with NSCLC carrying the BRAF G469A mutation achieved a PFS of 20.4 months. Here, BRAF is linked to non-small cell lung carcinoma.